Shasun Pharmaceuticals has surged 10% to Rs 187 after the company said that it has successfully completed US and Mexican drug regulator inspection at its active pharma ingredients (API) facility at Tamil Nadu.
The stock opened at Rs 170 and hit a high of Rs 197, also its record high on BSE. The trading volumes on the counter increased over five-fold with a combined 3.75 million shares changing hands till noon deals on BSE and NSE.
The company has successfully completed both US Food and Drug Administration (FDA) and Mexican COFEPRIS (Mexican Regulatory Authority) inspection at its API facility at Cuddalore Tamil Nadu, Shasun Pharma said in a statement.
Upon completion of the inspection, the US FDA authorities concluded that the facility, systems and practices comply with their requirements with minor 483sand on completion of inspection APIF concluded that Shasun’s compliance with current Good Manufacturing Practices (cGMP)are fully met and a formal GMP certificate will be issued by COFEPRIS in due course, it added.
The stock opened at Rs 170 and hit a high of Rs 197, also its record high on BSE. The trading volumes on the counter increased over five-fold with a combined 3.75 million shares changing hands till noon deals on BSE and NSE.
The company has successfully completed both US Food and Drug Administration (FDA) and Mexican COFEPRIS (Mexican Regulatory Authority) inspection at its API facility at Cuddalore Tamil Nadu, Shasun Pharma said in a statement.
Upon completion of the inspection, the US FDA authorities concluded that the facility, systems and practices comply with their requirements with minor 483sand on completion of inspection APIF concluded that Shasun’s compliance with current Good Manufacturing Practices (cGMP)are fully met and a formal GMP certificate will be issued by COFEPRIS in due course, it added.